United States - English - NLM (National Library of Medicine)

remedyrepack inc. - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. respiratory tract infections caused by mycoplasma pneumoniae. lymphogranuloma venereum caused by chlamydia trachomatis. psittacosis (ornithosis) caused by chlamydophila psittaci. trachoma caused by chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. inclusion conjunctivitis caused by chlamydia trachomatis. uncomplicated urethral, endocervical or rectal infections in adults caused by chlamydia trachomatis. nongonococcal urethritis caused by ureaplasma urealyticum. relapsing fever due to borrelia recurrentis. doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: chancroid caused by haemophilus ducreyi. plague due to yersinia pestis . tularemia due to francisella tularensis . cholera caused by vibrio cholerae . campylobacter fetus infections caused by campylobacter fetus . brucellosis due to brucella species (in conjunction with streptomycin). bartonellosis due to bartonella bacilliformis. granuloma inguinale caused by klebsiella granulomatis. because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: escherichia coli enterobacter aerogenes shigella species acinetobacter species respiratory tract infections caused by haemophilus influenzae. respiratory tract and urinary tract infections caused by klebsiella species. doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: upper respiratory infections caused by streptococcus pneumoniae . anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: uncomplicated gonorrhea caused by neisseria gonorrhoeae. syphilis caused by treponema pallidum. yaws caused by treponema pallidum subspecies pertenue. listeriosis due to listeria monocytogenes. vincent's infection caused by fusobacterium fusiforme. actinomycosis caused by actinomyces israelii. infections caused by clostridium species. in acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. in severe acne, doxycycline may be useful adjunctive therapy. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

intramed -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

geoschw -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate; doxycycline -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - ciprofloxacin hydrochloride - solution for infusion - 2 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciprofloxacin hydrochloride - film coated tablet - 250 base milligrams - fluoroquinolones

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciprofloxacin hydrochloride - film coated tablet - 500 base milligrams - fluoroquinolones

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciprofloxacin hydrochloride - film coated tablet - 750 base milligrams - fluoroquinolones